Recent

% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

errico51 8 posts  |  Last Activity: Jan 30, 2016 3:52 AM Member since: Sep 16, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Aschoff observed, The latest data support the view that NSI-566 cells demonstrate biological activity in all three indications and could lead to clinically meaningful treatment benefits. Neuralstem also provided anticipated timing for its NSI-566 programs. Final follow up from a Phase 2 trial in ALS (n=15) was completed in December 2015, and a larger Phase 2b efficacy trial for ALS is scheduled. Every NSI-566 treated patient in Phase 2b will receive 40 cervical and lumbar injections totaling 12 million NSI-566 cells, and endpoints including ALSFRS, grip strength, and vital capacity will be measured at 9 months. Neuralstem also plans to initiate a Phase 2/3 chronic stroke trial in China in 2H16, and continue its treatment of chronic spinal cord injury in a higher dose cohort...

    Sentiment: Strong Buy

  • Yesterday the most important newspaper in Italy, where I live, speaks about the drug. It's the first time I see. Google "Repubblica + nsi 189". It's a positive review.

    Sentiment: Strong Buy

  • Reply to

    Yahoo group?

    by mattd.account Aug 13, 2015 10:09 PM
    errico51 errico51 Aug 14, 2015 6:47 AM Flag

    Me too please

  • The triumph of idiocy.

  • errico51 errico51 Aug 11, 2015 2:01 PM Flag

    Aschoff wrote, “Neuralstem ended 2Q15 with about $23.7 million in cash, which should fund the company into 2016. The U.S. District Court of Maryland dismissed StemCells’ patent infringement case with prejudice in a case against Neuralstem, in favor of Neuralstem. The judge characterized StemCells’ patents as unenforceable. This is an important development because StemCells would have otherwise been a direct cell therapy competitor.”

    “Neuralstem is finalizing its regulatory and clinical plans to initiate a 200-patient multi-site Phase 2 trial with NSI-189 for MDD, which is expected to start in 2H15, following positive top-line Phase 1b data with NSI-189 for MDD from 2014. A larger Phase 2 efficacy trial with NSI-566 for ALS will start by YE15, and we expect a more thorough analysis of the last ALS trial results to also come by YE15. We expect Neuralstem to adopt an enriched enrollment and to recruit healthier patients that are more likely to benefit from NSI-566 therapy. We estimate that the refined patient population in the trial will still represent a majority of the 5,600 newly diagnosed patients.”, the analyst added.

  • I think -189 is worth $1.50 alone. I think -566 is probably worth $3

  • errico51 errico51 Jul 27, 2015 6:12 AM Flag

    Please provide key worlds to find this article. Thanks

  • Prejudice is a legal term with different meanings when used in criminal, civil or common law. Often the use of prejudice in legal context differs from the more common use of the word and thus has specific technical meanings implied by its use. Two of the more common applications of the word are as part of the terms "with prejudice" and "without prejudice". In general, an action taken with prejudice is essentially final; in particular, "dismissal with prejudice" would forbid a party from refiling the case, and might occur either because of misconduct on the part of the party who filed the claim or criminal complaint or could be the result of an out of court agreement or settlement. Dismissal without prejudice (in latin, "Salvis Juribus"[1]) would leave the party to option to refile, and is often a response to procedural or technical problems with the filing that the party could correct when filing again.

    Sentiment: Strong Buy

CUR
0.36+0.02(+6.82%)May 26 4:00 PMEDT